{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:10:11Z","timestamp":1792066211717,"version":"4.4.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000269","name":"Economic and Social Research Council","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office of the Scottish Government Health and Social Care Directorates","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University College London Hospitals NIHR Biomedical Research Centre","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"crossref","award":["295989"],"award-info":[{"award-number":["295989"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR North Thames Applied Research Collaboration","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Development Division"},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/V023373\/1"],"award-info":[{"award-number":["MR\/V023373\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218497\/Z\/19\/Z"],"award-info":[{"award-number":["218497\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012068","name":"Health and Care Research Wales","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS England","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","award":["HDR-23012"],"award-info":[{"award-number":["HDR-23012"]}],"id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCL Division of Psychiatry","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,3,22]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metformin is a pharmacological candidate to mitigate second-generation antipsychotic (SGA)-induced weight gain in patients diagnosed with severe mental illnesses (SMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the incidence, prevalence and demographic patterns of metformin co-prescription among patients diagnosed with SMI initiating SGAs. To estimate the impact of metformin co-prescription on weight over 2 years post-SGA initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study of patients diagnosed with SMI initiating aripiprazole, olanzapine, quetiapine or risperidone in 2005\u20132019 using primary care data from Clinical Practice Research Datalink. We estimated cumulative incidence and period prevalences of co-prescription and explored prescribing differences by demographic and clinical factors. We compared weight change among patients prescribed an SGA-only versus an SGA plus metformin, accounting for confounders using linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Among 26\u2009537 patients initiating SGAs, 4652 were ever prescribed metformin and 21\u2009885 were not. The two-year incidence of first metformin prescription was 3.3%. The SGA plus metformin group were more ethnically diverse, had greater social deprivation, more comorbidities and higher baseline weight (mean 90.4 vs 76.8\u2009kg). By 2 years post-SGA initiation, mean weight in the SGA-only group had changed by +4.16% (95% CI \u22121.26 to +9.58) compared with \u22120.65% (95% CI \u22124.26 to +2.96) in the SGA plus metformin group. After confounder adjustment, the 2-year mean difference in weight with metformin co-prescription was \u22121.48 kg (95% CI \u22124.03 to 1.07) among females and \u22121.84 kg (95% CI \u22124.67 to 0.98) among males.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metformin is infrequently co-prescribed, despite apparent efficacy and guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Primary and secondary care collaboration should be strengthened and barriers to co-prescribing addressed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2024-301505","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:00:48Z","timestamp":1743624048000},"page":"e301505","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Co-prescription of metformin and antipsychotics in severe mental illness: a UK primary care cohort study"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-3426","authenticated-orcid":false,"given":"Luiza","family":"Farache Trajano","sequence":"first","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3862","authenticated-orcid":false,"given":"Joseph F","family":"Hayes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"},{"name":"North London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-938X","authenticated-orcid":false,"given":"Naomi","family":"Launders","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M","family":"Davies","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"},{"name":"Department of Statistical Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-1539","authenticated-orcid":false,"given":"David P J","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"},{"name":"North London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Richards-Belle","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2026010702310179000_28.1.e301505.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38881.382755.2F"},{"key":"2026010702310179000_28.1.e301505.2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.157685"},{"key":"2026010702310179000_28.1.e301505.3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"The Lancet"},{"key":"2026010702310179000_28.1.e301505.4","doi-asserted-by":"crossref","unstructured":"Richards-Belle A , Launders N , Hardoon S , et al . Prescribing of antipsychotics for people diagnosed with severe mental illness in uk primary care: a 20-year investigation of who receives treatment, with which agents, and at what doses. Psychiatry and Clinical Psychology [Preprint] 2024. doi:10.1101\/2024.03.26.24304727","DOI":"10.1101\/2024.03.26.24304727"},{"key":"2026010702310179000_28.1.e301505.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"2026010702310179000_28.1.e301505.6","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21036"},{"key":"2026010702310179000_28.1.e301505.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.07.007"},{"key":"2026010702310179000_28.1.e301505.8","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2021-300291"},{"key":"2026010702310179000_28.1.e301505.9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.117.202606"},{"key":"2026010702310179000_28.1.e301505.10","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.2.242"},{"key":"2026010702310179000_28.1.e301505.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00498-X"},{"key":"2026010702310179000_28.1.e301505.12","doi-asserted-by":"crossref","unstructured":"Dayabandara M , Hanwella R , Ratnatunga S , et al . . NDT 2017;Volume 13:2231\u201341. 10.2147\/NDT.S113099","DOI":"10.2147\/NDT.S113099"},{"key":"2026010702310179000_28.1.e301505.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112276","article-title":"The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis","volume":"9","author":"Bruins","year":"2014","journal-title":"PLoS One"},{"key":"2026010702310179000_28.1.e301505.14","doi-asserted-by":"crossref","first-page":"114818","DOI":"10.1016\/j.psychres.2022.114818","article-title":"Improving physical activity and diet in patients with severe mental disorders: Results from the LIFESTYLE multicentric, real-world randomized controlled trial","volume":"317","author":"Luciano","year":"2022","journal-title":"Psychiatry Res"},{"key":"2026010702310179000_28.1.e301505.15","unstructured":"Metformin hydrochloride | drugs | bnf content published by nice. Available: https:\/\/bnf.nice.org.uk\/drugs\/metformin-hydrochloride\/ [Accessed 28 Nov 2024]."},{"key":"2026010702310179000_28.1.e301505.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2026010702310179000_28.1.e301505.17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu030"},{"key":"2026010702310179000_28.1.e301505.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-0785-y","article-title":"Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"10","author":"Jiang","year":"2020","journal-title":"Transl Psychiatry"},{"key":"2026010702310179000_28.1.e301505.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.06.003"},{"key":"2026010702310179000_28.1.e301505.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2007.56-b"},{"key":"2026010702310179000_28.1.e301505.21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"2026010702310179000_28.1.e301505.22","unstructured":"\u201823\/169 Metformin to prevent antipsychotic-induced weight gain | NIHR,\u2019 Available: https:\/\/www.nihr.ac.uk\/23169-metformin-prevent-antipsychotic-induced-weight-gain [Accessed 28 Nov 2024]."},{"key":"2026010702310179000_28.1.e301505.23","unstructured":"Surveillance proposals | Evidence | Psychosis and schizophrenia in adults: prevention and management | Guidance | NICE, Available: https:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/2023-exceptional-surveillance-of-psychosis-and-schizophrenia-in-children-young-people-and-adults-nice-guidelines-cg155-and-cg178-13244105197\/chapter\/Surveillance-proposals [Accessed 28 Nov 2024]."},{"key":"2026010702310179000_28.1.e301505.24","unstructured":"Overview | Psychosis and schizophrenia in adults: prevention and management | Guidance | NICE, Available: https:\/\/www.nice.org.uk\/guidance\/cg178 [Accessed 28 Nov 2024]."},{"key":"2026010702310179000_28.1.e301505.25","doi-asserted-by":"crossref","unstructured":"Carolan A , Hynes-Ryan C , Agarwal SM , et al . Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophr Bull 2024.:sbae205. doi:10.1093\/schbul\/sbae205","DOI":"10.1093\/schbul\/sbae205"},{"key":"2026010702310179000_28.1.e301505.26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2026010702310179000_28.1.e301505.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026010702310179000_28.1.e301505.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004520","article-title":"Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation","volume":"22","author":"Richards-Belle","year":"2025","journal-title":"PLoS Med"},{"key":"2026010702310179000_28.1.e301505.29","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-015-0574-0","article-title":"Gastroenterology issues in schizophrenia: why the gut matters","volume":"17","author":"Severance","year":"2015","journal-title":"Curr Psychiatry Rep"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2024-301505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:31:33Z","timestamp":1767781893000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2024-301505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjment-2024-301505"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2024-301505","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.03.24318407","asserted-by":"object"}]},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}